Last 12 months
Inside the activity.
1 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2017 Filed May 17, 2017 21:49 UTC |
KROLL MARK WDirector
|
SaleCommon Stock | 300 | $41.48 | $12,442.50 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 10 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,590 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC |
KROLL MARK WDirector
|
SaleCommon Stock | 1,771 | $41.47 | $73,443.37 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 9 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,890 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC |
KROLL MARK WDirector
|
SaleCommon Stock | 300 | $41.47 | $12,439.50 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 8 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,661 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC |
KROLL MARK WDirector
|
SaleCommon Stock | 500 | $41.46 | $20,730.00 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 7 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,961 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC |
KROLL MARK WDirector
|
SaleCommon Stock | 100 | $41.46 | $4,145.80 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 6 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,461 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC |
KROLL MARK WDirector
|
SaleCommon Stock | 53 | $41.45 | $2,196.90 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 5 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,561 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC |
KROLL MARK WDirector
|
SaleCommon Stock | 200 | $41.45 | $8,290.00 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 4 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,614 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC |
KROLL MARK WDirector
|
SaleCommon Stock | 100 | $41.45 | $4,144.50 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 3 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,814 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC |
KROLL MARK WDirector
|
SaleCommon Stock | 100 | $41.44 | $4,144.00 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 2 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,914 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC |
KROLL MARK WDirector
|
Exercise / conversionCommon Stock | 8,580 | $27.24 | $233,719.20 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2017 Filed May 16, 2017 00:29 UTC |
FOOTE SUSAN BARTLETTDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 8,196 | $0.00 Strike: $36.37 | $0.00 |
DisclosureSEC source: 0001127602-17-018156 · form4.xml · derivative · entry 5 FOOTE SUSAN BARTLETT · CIK 0001244063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,196 shares Expires 2019-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| May 11, 2017 Filed May 16, 2017 00:29 UTC |
FOOTE SUSAN BARTLETTDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 7,118 | $0.00 Strike: $34.41 | $0.00 |
DisclosureSEC source: 0001127602-17-018156 · form4.xml · derivative · entry 4 FOOTE SUSAN BARTLETT · CIK 0001244063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,118 shares Expires 2018-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| May 11, 2017 Filed May 16, 2017 00:29 UTC |
FOOTE SUSAN BARTLETTDirector
|
SaleCommon Stock | 15,314 | $41.78 | $639,818.92 |
DisclosureSEC source: 0001127602-17-018156 · form4.xml · nonDerivative · entry 3 FOOTE SUSAN BARTLETT · CIK 0001244063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,251 F1 · price: Represents weighted average of trades between $41.72 and $41.91 Read SEC document |
| May 11, 2017 Filed May 16, 2017 00:29 UTC |
FOOTE SUSAN BARTLETTDirector
|
Exercise / conversionCommon Stock | 8,196 | $36.37 | $298,088.52 |
DisclosureSEC source: 0001127602-17-018156 · form4.xml · nonDerivative · entry 2 FOOTE SUSAN BARTLETT · CIK 0001244063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2017 Filed May 16, 2017 00:29 UTC |
FOOTE SUSAN BARTLETTDirector
|
Exercise / conversionCommon Stock | 7,118 | $34.41 | $244,894.79 |
DisclosureSEC source: 0001127602-17-018156 · form4.xml · nonDerivative · entry 1 FOOTE SUSAN BARTLETT · CIK 0001244063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 24, 2017 Filed Apr 27, 2017 21:19 UTC |
GELBMAN RONALD GDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 8,580 | $0.00 Strike: $27.24 | $0.00 |
DisclosureSEC source: 0001127602-17-015752 · form4.xml · derivative · entry 3 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,580 shares Expires 2017-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| March 24, 2017 Filed Apr 27, 2017 21:19 UTC |
GELBMAN RONALD GDirector
|
SaleCommon Stock | 8,580 | $40.00 | $343,200.00 |
DisclosureSEC source: 0001127602-17-015752 · form4.xml · nonDerivative · entry 2 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,688 F1 · shares: Cashless exercise and sale of net shares pursuant to a 10b5-1 trading plan. Read SEC document |
| March 24, 2017 Filed Apr 27, 2017 21:19 UTC |
GELBMAN RONALD GDirector
|
Exercise / conversionCommon Stock | 8,580 | $27.24 | $233,719.20 |
DisclosureSEC source: 0001127602-17-015752 · form4.xml · nonDerivative · entry 1 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 22:21 UTC |
Basil Michelle LEVP and General Counsel
|
GrantPerformance Shares · Derivative | 9,758 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-010886 · form4.xml · derivative · entry 3 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,516 Underlying: Common Stock · 9,758 shares Expires 2019-12-31 F3 · derivative.exercise_date: Performance Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on the performance of Haemonetics stock price relative to the Total Shareholder Return of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600. The number of Performance Share Units (and therefore the number of shares payable) will depend on the Company's stock price performance between October 1, 2016 and September 30, 2019. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to twice the target amount in column 5. The Performance Share Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d). Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 22:21 UTC |
Basil Michelle LEVP and General Counsel
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 19,490 | $38.43 Strike: $38.43 | $749,000.70 |
DisclosureSEC source: 0001127602-17-010886 · form4.xml · derivative · entry 2 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,490 Underlying: Common Stock · 19,490 shares Expires 2024-03-06 F2 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 22:21 UTC |
Basil Michelle LEVP and General Counsel
|
GrantCommon Stock | 4,879 | $38.43 | $187,499.97 |
DisclosureSEC source: 0001127602-17-010886 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,879 F1 · shares: Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan. Read SEC document |
| January 13, 2017 Filed May 23, 2018 21:09 UTC |
Ryding Neil Mr.EVP, Global Manufacturing
|
Tax withholdingCommon Stock | 3,303 | $40.32 | $133,176.96 |
DisclosureSEC source: 0001127602-18-018570 · form4.xml · nonDerivative · entry 2 Ryding Neil Mr. · CIK 0001654614 · EVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,022 F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 22:00 UTC |
GELBMAN RONALD GDirector
|
SaleCommon Stock | 5,683 | $40.30 | $229,024.90 |
DisclosureSEC source: 0001127602-16-070019 · form4.xml · nonDerivative · entry 1 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,688 Read SEC document |
| October 25, 2016 Filed Oct 28, 2016 00:05 UTC |
BURZIK CATHERINE MDirector
|
GrantCommon Stock | 4,969 | $34.21 | $169,989.49 |
DisclosureSEC source: 0001127602-16-065437 · form4.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,969 F1 · shares: Restricted Stock Unit Grant which vest 100% on the first anniversary of the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan. Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 23:56 UTC |
Jesse SandraEVP and Chief Legal Officer
|
GrantPerformance Shares · Derivative | 6,577 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-065433 · form4.xml · derivative · entry 3 Jesse Sandra · CIK 0001533401 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,577 Underlying: Common Stock · 6,577 shares Expires 2019-12-31 F3 · derivative.exercise_date: Performance Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on the performance of Haemonetics stock price relative to the Total Shareholder Return of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600. The number of Performance Share Units (and therefore the number of shares payable) will depend on the Company's stock price performance between October 1, 2016 and September 30, 2019. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to twice the target amount in column 5. The Performance Share Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d). Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 23:56 UTC |
Jesse SandraEVP and Chief Legal Officer
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 14,187 | $3,421.00 Strike: $34.21 | $48,533,727.00 |
DisclosureSEC source: 0001127602-16-065433 · form4.xml · derivative · entry 2 Jesse Sandra · CIK 0001533401 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,187 Underlying: Common Stock · 14,187 shares Expires 2023-10-25 F2 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 23:56 UTC |
Jesse SandraEVP and Chief Legal Officer
|
GrantCommon Stock | 3,288 | $34.21 | $112,482.48 |
DisclosureSEC source: 0001127602-16-065433 · form4.xml · nonDerivative · entry 1 Jesse Sandra · CIK 0001533401 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,166 F1 · shares: Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan. Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 23:07 UTC |
Selman ByronPresident, Global Markets
|
GrantPerformance Shares · Derivative | 7,673 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-065409 · form4.xml · derivative · entry 3 Selman Byron · CIK 0001646937 · President, Global Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,673 Underlying: Common Stock · 7,673 shares Expires 2019-12-31 F3 · derivative.exercise_date: Performance Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on the performance of Haemonetics stock price relative to the Total Shareholder Return of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600. The number of Performance Share Units (and therefore the number of shares payable) will depend on the Company's stock price performance between October 1, 2016 and September 30, 2019. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to twice the target amount in column 5. The Performance Share Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d). Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 23:07 UTC |
Selman ByronPresident, Global Markets
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 16,551 | $34.21 Strike: $34.21 | $566,209.71 |
DisclosureSEC source: 0001127602-16-065409 · form4.xml · derivative · entry 2 Selman Byron · CIK 0001646937 · President, Global Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,551 Underlying: Common Stock · 16,551 shares Expires 2023-10-25 F2 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 23:07 UTC |
Selman ByronPresident, Global Markets
|
GrantCommon Stock | 3,836 | $34.21 | $131,229.56 |
DisclosureSEC source: 0001127602-16-065409 · form4.xml · nonDerivative · entry 1 Selman Byron · CIK 0001646937 · President, Global Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,318 F1 · shares: Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan. Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 23:13 UTC |
Fusco DavidEVP, Global Human Resources
|
GrantPerformance Shares · Derivative | 5,261 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-065412 · form4.xml · derivative · entry 3 Fusco David · CIK 0001649182 · EVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,261 Underlying: Common Stock · 5,261 shares Expires 2019-12-31 F3 · derivative.exercise_date: Performance Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on the performance of Haemonetics stock price relative to the Total Shareholder Return of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600. The number of Performance Share Units (and therefore the number of shares payable) will depend on the Company's stock price performance between October 1, 2016 and September 30, 2019. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to twice the target amount in column 5. The Performance Share Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d). Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 23:13 UTC |
Fusco DavidEVP, Global Human Resources
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 11,349 | $34.21 Strike: $34.21 | $388,249.29 |
DisclosureSEC source: 0001127602-16-065412 · form4.xml · derivative · entry 2 Fusco David · CIK 0001649182 · EVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,349 Underlying: Common Stock · 11,349 shares Expires 2023-10-25 F2 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 23:13 UTC |
Fusco DavidEVP, Global Human Resources
|
GrantCommon Stock | 2,630 | $34.21 | $89,972.30 |
DisclosureSEC source: 0001127602-16-065412 · form4.xml · nonDerivative · entry 1 Fusco David · CIK 0001649182 · EVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,867 F1 · shares: Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan. Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 23:03 UTC |
Ryding Neil Mr.EVP, Global Manufacturing
|
GrantPerformance Shares · Derivative | 6,577 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-065407 · form4.xml · derivative · entry 3 Ryding Neil 122-62-507 · CIK 0001654614 · EVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,577 Underlying: Common Stock · 6,577 shares Expires 2019-12-31 F3 · derivative.exercise_date: Performance Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on the performance of Haemonetics stock price relative to the Total Shareholder Return of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600. The number of Performance Share Units (and therefore the number of shares payable) will depend on the Company's stock price performance between October 1, 2016 and September 30, 2019. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to twice the target amount in column 5. The Performance Share Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d). Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 23:03 UTC |
Ryding Neil Mr.EVP, Global Manufacturing
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 14,187 | $34.21 Strike: $34.21 | $485,337.27 |
DisclosureSEC source: 0001127602-16-065407 · form4.xml · derivative · entry 2 Ryding Neil 122-62-507 · CIK 0001654614 · EVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,187 Underlying: Common Stock · 14,187 shares Expires 2023-10-25 F2 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 23:03 UTC |
Ryding Neil Mr.EVP, Global Manufacturing
|
GrantCommon Stock | 3,288 | $34.21 | $112,482.48 |
DisclosureSEC source: 0001127602-16-065407 · form4.xml · nonDerivative · entry 1 Ryding Neil 122-62-507 · CIK 0001654614 · EVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,275 F1 · shares: Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan. Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 22:44 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
GrantPerformance Shares · Derivative | 20,827 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-065405 · form4.xml · derivative · entry 3 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,827 Underlying: Common Stock · 20,827 shares Expires 2019-12-31 F3 · derivative.exercise_date: Performance Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on the performance of Haemonetics stock price relative to the Total Shareholder Return of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600. The number of Performance Share Units (and therefore the number of shares payable) will depend on the Company's stock price performance between October 1, 2016 and September 30, 2019. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to twice the target amount in column 5. The Performance Share Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d). Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 22:44 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 44,926 | $34.21 Strike: $34.21 | $1,536,918.46 |
DisclosureSEC source: 0001127602-16-065405 · form4.xml · derivative · entry 2 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,926 Underlying: Common Stock · 44,926 shares Expires 2023-10-25 F2 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 22:44 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
GrantCommon Stock | 10,413 | $34.21 | $356,228.73 |
DisclosureSEC source: 0001127602-16-065405 · form4.xml · nonDerivative · entry 1 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,413 F1 · shares: Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan. Read SEC document |
| October 25, 2016 Filed Nov 15, 2017 23:10 UTC |
Goldstein DanChief Accounting Officer
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,826 | $34.21 Strike: $34.21 | $199,307.46 |
DisclosureSEC source: 0001127602-17-032257 · form4.xml · derivative · entry 11 Goldstein Dan · CIK 0001722327 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,826 Underlying: Common Stock · 5,826 shares Expires 2023-10-25 F2 · shares: Non-qualified stock option grant providing a right to buy shares of common stock exercisable in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| October 25, 2016 Filed Nov 15, 2017 23:10 UTC |
Goldstein DanChief Accounting Officer
|
GrantCommon Stock | 1,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-032257 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,747 F1 · shares: Restricted Stock Units which vest 25% per year over 4 years following the grant date. Read SEC document |
| October 20, 2016 Filed May 23, 2018 21:09 UTC |
Ryding Neil Mr.EVP, Global Manufacturing
|
SaleCommon Stock | 351 | $34.16 | $11,990.16 |
DisclosureSEC source: 0001127602-18-018570 · form4.xml · nonDerivative · entry 1 Ryding Neil Mr. · CIK 0001654614 · EVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,325 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.